Skip to content
Search

Latest Stories

PSNC rejects government plan to remove transitional payments calling it a 'spreadsheet balancing act'

The Pharmaceutical Services Negotiating Committee (PSNC) has refused to accept the Department of Health and Social Care (DHSC)’s decision to get rid of 'transitional payments' from February 2023.

The pharmacy negotiator said that ‘any reductions in payments at this point will be impossible for community pharmacy contractors to manage financially.’


“We are also continuing to be clear with officials and ministers that CPCF funding needs an urgent uplift to help businesses to cope with soaring costs being driven by inflation and the workforce crisis. We put a comprehensive business case to the government for this uplift in the last CPCF negotiations.”

The latest 'transitional payments decision' by the Department follows the announcement last year that the value of the these payments would be phased down over the second half of 2022/23 and will be based on the latest monitoring and analysis of funding delivery.

PSNC says it submitted a fully-costed bid for a 'Pharmacy First' service in its last round of negotiations alongside the case for an uplift to core CPCF funding. Both of these were refused.

'Spreadsheet balancing act'

Janet Morrison, PSNC chief executive, said: “The Department’s removal of the Transitional Payments could not come at a worse time for community pharmacy businesses who by the government’s own admission have been subjected to years of funding cuts.

"Pharmacies are on the brink of collapse and removing these payments now may be the final straw for some: we have made that absolutely clear.

"While we know how constrained public funding is, this spreadsheet balancing act has real world costs in terms of businesses, livelihoods, jobs, healthcare and community resources.

"We will keep making that case in the strongest terms: the public and NHS rely heavily on pharmacies and we are the solution to many of the health service’s current problems, but all of this will be lost if we are squeezed to the point of collapse. The #saveourpharmacies campaign which we and the other national pharmacy bodies have launched will be critical in reinforcing all of this.”

'Catastrophic policy choice'

Peter Cattee, chair of PSNC’s Funding and Contract Subcommittee and a negotiating team member, said: “The government’s refusal to move away from the five-year deal given our current situation – one that is not of our making nor could have been foreseen as inflation and cost of living crisis bite, and our workforce is decimated, largely by NHS decisions – is a policy choice that is going to be catastrophic for some pharmacies and ultimately for patients.

"Contractors now have little control over their own businesses and we must continue to take whatever action is within our power to change government minds and that decision before we see chaos in the network.”

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less